-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
Review
(2064) Views (798) Full article downloads
Authors: Mohamed Mahdi-Rogers, Yusuf A Rajabally
Published Date March 2010
Volume 2010:4 Pages 45 - 49
DOI: http://dx.doi.org/10.2147/BTT.S4881
Mohamed Mahdi-Rogers, Yusuf A Rajabally
Neuromuscular Clinic, Department of Neurology, University Hospitals of Leicester, Leicester, UK
Abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired heterogeneous disorder of immune origin affecting the peripheral nerves, causing motor weakness and sensory symptoms and signs. The precise pathophysiology of CIDP remains uncertain although B and T cell mechanisms are believed to be implicated. Intravenous immunoglobulins (IVIg) have been shown in a number of trials to be an effective treatment for CIDP. IVIg is thought to exert its immunomodulatory effects by affecting several components of the immune system including B-cells, T-cells, macrophages and complement. This article provides an overview of the pathogenesis of CIDP and of its treatment with IVIg.
Keywords: chronic inflammatory demyelinating polyneuropathy, intravenous immunoglobulin, pathogenesis, treatment
Readers of this article also read:
Current available therapies and future directions in the treatment of malignant gliomas
Safety of etanercept in elderly subjects with rheumatoid arthritis
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Use of clofarabine for acute childhood leukemia
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
New and emerging treatment approaches to lupus
Gaucher disease: clinical profile and therapeutic developments
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




